Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $126.00.

LNTH has been the topic of several research analyst reports. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley increased their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Finally, JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st.

Lantheus Stock Performance

NASDAQ:LNTH opened at $105.55 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm has a 50-day moving average of $104.91 and a two-hundred day moving average of $82.74. The stock has a market cap of $7.33 billion, a P/E ratio of 16.11 and a beta of 0.50. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the business posted $1.40 EPS. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, research analysts expect that Lantheus will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares in the last quarter. Moody National Bank Trust Division boosted its holdings in shares of Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after acquiring an additional 162 shares in the last quarter. Shaker Investments LLC OH boosted its holdings in shares of Lantheus by 0.7% in the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after acquiring an additional 182 shares in the last quarter. NBC Securities Inc. boosted its holdings in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 191 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.